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functions as an endocrine factor. In obese animals, elevation of plasma FGF21 levels by either
pharmacological or genetic approaches reduces body weight, decreases hyperglycemia and
hyperlipidemia, alleviates fatty liver and increases insulin sensitivity. FGF21 exerts its pleiotropic
metabolic effects through its actions on multiple targets, including adipose tissue, liver, brain and
pancreas. The expression of FGF21 is under the control of both peroxisome proliferator-activated
receptor gamma (PPARg) and peroxisome proliferator-activated receptor alpha (PPARa). A
growing body of evidence suggests that the metabolic beneﬁts of these two nuclear receptors are
mediated in part by induction of FGF21. In humans, plasma levels of FGF21 are elevated in obese
subjects and patients with type 2 diabetes, but are reduced in patients with autoimmune diabetes.
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Metabolic actions of FGF21 351molecular pathways underlying its actions, and also discusses the future prospective of developing
FGF21 or its agonists as therapeutic agents for obesity-related medical complications.
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Glucose and lipid metabolism is tightly controlled by a large
number of metabolic hormones secreted from different endo-
crine organs. Notable among them are the pancreatic hor-
mones (insulin and glucagon), adipose tissue-secreted
adipokines (such as leptin and adiponectin), gut-derived
hormones (such as glucagon-like peptide-1 and ghrelin) and
adrenal hormones (such as glucocorticoids). These metabolic
hormones form an integrated network to control substrate
utilization and energy balance in response to nutritional
status. Aberrant secretion and/or dysfunction of metabolic
hormones are important contributor to obesity-related cardio-
metabolic complications, including type 2 diabetes, nonalco-
holic fatty liver disease, hypertension, coronary heart disease
and stroke1–3.
Several members of the ﬁbroblast growth factors (FGFs)
superfamily, including FGF15/19, FGF21 and FGF23, has
recently been identiﬁed to play important roles in metabolic
regulations4. Unlike the classic FGFs that require heparin for
stable binding to the FGF receptors (FGFRs), the three
endocrine members of the FGF superfamily lack the
heparin-binding property, and therefore can be released into
the circulation to act as endocrine factors4. These hormone-
like FGFs are involved in the regulation of diverse metabolic
pathways: FGF15/19 controls cholesterol/bile acid synthesis,
FGF23 modulates phosphate/vitamin D metabolism, and
FGF21 regulates glucose and lipid metabolism4. Due to the
multiple metabolic beneﬁts of FGF21 on energy homeostasis
and insulin sensitivity5–7, it has attracted great attention as a
potential therapeutic candidate for obesity-related medical
complications.2. Pharmacological effects of FGF21
The metabolic activity of FGF21 was ﬁrst discovered by
Kharitonenkov and colleagues in a cell-based high throughput
screening as a positive hit for its ability to induce glucose
uptake in adipocytes5. Therapeutic administration of recom-
binant FGF21 in both db/db diabetic mice and dietary obese
mice lowers blood glucose and triglyceride levels, and also
reverses hepatic steatosis and improves insulin sensitivity5,8.
Transgenic mice with liver-speciﬁc overexpression of FGF21
are resistant to diet-induced obesity, possibly due to increased
energy expenditure9. Likewise, chronic administration of
FGF21 to diabetic rhesus monkey for a period of 6 weeks
causes a dramatic decline in fasting levels of blood glucose,
fructosamine, insulin and glucagon, and also improves lipid
proﬁles, including lowering of triglycerides and low-density
lipoprotein cholesterol and raising of high-density lipoprotein
cholesterol6. Notably, FGF21 does not induce mitogenicity
and hypoglycemia at any dose tested in both rodents andrhesus monkeys5,6, demonstrating that FGF21 exhibits ther-
apeutic characteristics necessary for effective treatment of
diabetes and its complications.
However, it is of importance to note that therapeutic doses
of recombinant FGF21 used for these studies are substantially
higher than those in physiological concentrations. It is
currently unclear whether the requirement of supraphysiolo-
gical doses for effective therapeutic intervention is due to the
low bioactivity of recombinant FGF21 generated from E. coli,
or due to FGF21 resistance in obese/diabetic animals10. Since
FGF21 knockout (KO) mice do not develop either hypergly-
cemia or insulin resistance11,12, it is also possible that the
therapeutic beneﬁts of recombinant FGF21 on glucose home-
ostasis are only of pharmacological interest, but not of
physiological relevance.3. Metabolic actions of FGF21 on its major target tissues
3.1. Hepatic FGF21 functions
The liver is a major site for both production and actions of
FGF218,13. The hepatic expression and plasma levels of
FGF21 in mice are markedly elevated upon fasting, but are
suppressed by re-feeding14–16. Fasting-induced hepatic expres-
sion of FGF21 is mediated by PPARa, a ligand-activated
transcriptional factor that plays a central role in controlling
lipid metabolism and energy homeostasis15. The mRNA
expression of FGF21 in both mouse livers and human primary
hepatocytes are strongly induced by the PPARa agonists
fenoﬁbrates, whereas both fasting- and fenoﬁbrates-induced
expression of FGF21 is abrogated in PPARa KO mice15.
A growing body of evidence suggests that FGF21 serves as a
key downstream target of PPARa mediating the metabolic
adaptation responses to fasting/starvation, including ketogen-
esis, fatty acid oxidation and gluconeogenesis (Fig. 1).
3.1.1. Modulation of ketogenesis by FGF21
In response to fasting/starvation, hepatic metabolism is pro-
grammed to oxide fatty acids and to produce fuel in the form of
ketone bodies (b-hydroxybutyrate, acetoacetate and acetone),
which progressively becomes the major energy source for the
brain17. Several independent studies have demonstrated that
FGF21 is required for fasting-induced ketogenesis in mice14,15.
Adenovirus-mediated in vivo knockdown of hepatic FGF21
expression in a ketogenic diet-fed mice causes fatty liver, lipemia,
and reduced serum ketones, and this change is associated with
altered expression of key genes involved in hepatic lipid
metabolism and ketone production15. Vice versa, the transgenic
mice with liver-speciﬁc overexpression of FGF21 exhibit a
signiﬁcant increase in serum concentrations of ketone bodies
and a concurrent reduction in serum and hepatic triglyceride
concentrations14,15. Furthermore, impaired ketone production
Figure 1 FGF21 acts as a downstream target of PPARa exerting multiple biological effects in hepatocytes. In response to fasting, free
fatty acids (FFA) released from adipocytes acts as an endogenous ligand to activate PPARa, which induces FGF21 expression via
transcriptional activation. FGF21 released from hepatocytes may act in an endocrine or autocrine/paracrine manner modulating
ketogenesis, gluconeogenesis, fatty acid oxidation, growth hormone (GH) resistance and carcinogenesis. Note that whether or not
hepatocytes are a direct target of FGF21 is still a matter of debate.
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be partially restored by administration of recombinant FGF21.
However, two independent studies on FGF21 KO mice have
yielded inconsistent data on the role of FGF21 in ketogen-
esis11,18. FGF21 KO mice generated by Flier’s group display
impaired adaption to ketosis induced by a ketogenic diet, which
is accompanied by severe hepatic steatosis and body weight gain
as compared with wild type mice18. By contrast, Itoh and
colleagues demonstrated a modest increase in serum b-hydro-
xybutyrate levels in FGF21 KO mice fasted for 24 h, suggesting
an increased ketogenesis11. The differences in genetic back-
ground, diet composition and/or study protocols may account
for the inconsistent observations between the two reports.
In humans, chronic treatments with the PPARa agonist
fenoﬁbrates increase the circulating concentrations of
FGF2119. However, ketogenic diet has no obvious inﬂuence
on circulating FGF2120. The physiological roles of FGF21 in
regulating ketogenesis need further investigation.3.1.2. FGF21 and hepatic gluconeogenesis
PPARa is an important player in fasting-induced hepatic
gluconeogenesis. PPARa KO mice exhibit hypoglycemia upon
fasting, which is accompanied by impaired expression of
gluconeogenic genes21. Likewise, FGF21 has been implicated
in the regulation of gluconeogenesis during the progression
from fasting to starvation12. Such an effect of FGF21 is
mediated by induction of hepatic expression of peroxisome
proliferator-activated receptor coactivator protein 1 a
(PGC1a), a transcriptional coactivator that controls the
expression of gluconeogenic genes22,23. The inductive effects
of FGF21 on expression of the two gluconeogenic genes
(glucose-6-phosphatase and phosphoenolpyruvate carboxyki-
nase) are virtually abrogated in PGC1a KO mice24. Vice versa,
mice lacking FGF21 fail to fully induce PGC1a expression in
response to fasting and have impaired gluconeogenesis12.
Notably, direct incubation of either isolated, perfused mouse
liver or primary cultures of rat or mouse hepatocytes with
FGF21 has no obvious effects on PGC1a expression, suggest-
ing that FGF21 might stimulate gluconeogenesis through an
indirect mechanism.
In contrast to the aforementioned ﬁndings, another study
from Fisher and colleagues showed that FGF21 acts directlyon the liver to stimulate the expression of gluconeogenic
genes24. This study also found that FGF21 can still induce
the same degree of gluconeogenic gene expression in mice with
liver-speciﬁc ablation of PGC1a as seen in wild-type mice, thus
excluding the involvement of PGC1a in FGF21-induced
glucose production. The precise role of FGF21 on hepatic
gluconeogenesis and the underlying mechanisms require
further clariﬁcation.
3.1.3. FGF21 and fatty aid oxidation
PPARa is a master regulator of fatty acid oxidation, by
inducing the expression of a cluster of key genes involved in
this process25. A growing body of evidence suggests that
induction of hepatic fatty acid oxidation by PPARa is
mediated in part by FGF21. RNAi-mediated suppression of
FGF21 expression causes impaired ketogenic diet-induced
fatty acid oxidation and severe hepatic steatosis, whereas
chronic treatment with recombinant FGF21 reverses fatty
liver in diet-induced obese mice8. A recent study by Li and
colleagues26 found that sodium butyrate, a dietary compound
with protective effects against diet-induced obesity and dysli-
pidemia, increases hepatic expression and plasma levels of
FGF21 in mice. Noticeably, the ability of sodium butyrate to
increase energy expenditure and fatty acid oxidation was
abrogated in FGF21 KO mice. In humans, plasma levels of
FGF21 are signiﬁcantly elevated in patients with fatty liver
disease27,28, and are positively correlated with the liver fat
percentage and the degree of steatosis29. It is currently unclear
whether elevated plasma FGF21 levels are due to the com-
pensatory responses or the presence of FGF21 resistance to
fatty acid oxidation.
3.1.4. FGF21 and growth hormone (GH) resistance
GH is synthesized and secreted by the anterior pituitary to
regulate growth and metabolism. Many GH actions are
mediated by induction of hepatic expression of insulin-like
growth factor 1 (IGF-1)30. Starvation is known to block the
growth actions of GH by decreasing hepatic production of
IGF-1 through mechanisms that are not well understood. In
this connection, FGF21 has been proposed as a key mediator
conferring the starvation-induced inhibition on the GH/IGF-1
axis, by suppression of the active form of signal transducer
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a reduction of IGF-1 expression31. Furthermore, FGF21 also
induces the expression of IGF-1 binding protein-1 and
suppressor of cytokine signaling 2, which further blunt GH
signaling. Consistent with this report, FGF21 KO mice exhibit
greater body and tibial growth than their wild-type littermates
after 4 weeks of food restriction, whereas single injection of
GH induces greater hepatic activation of STAT5 and induc-
tion of IGF-1 in FGF21 KO mice than in wild-type mice32.
The suppressive effect of FGF21 on GH signaling is also
supported by another ﬁnding showing that FGF21 serves as a
negative feedback regulator to block GH-induced lipolysis in
adipocytes33. Suppression of hepatic IGF-1 production by
FGF21 may also explain the delayed onset of chemically-
induced hepatocarcinogenesis30,34. Consistent with these ani-
mal-based ﬁndings, plasma levels of FGF21 are signiﬁcantly
elevated in patients with anorexia nervosa, a state of chronic
nutritional deprivation characterized by GH resistance with
elevated GH levels and decreased levels of IGF-135. In subjects
with elevated FGF21 levels, there was a strong inverse
association between FGF21 and IGF-1, suggesting that
FGF21 may mediate GH resistance in humans.
3.2. FGF21 actions in adipose tissue
White adipocytes are another major target cells of FGF21,
where it stimulates glucose uptake, modulates lipolysis,
enhances mitochondrial oxidative capacity, and potentiates
PPARg activity5,7,11,14,36,37 (Fig. 2). There is also good
evidence that FGF21 is involved in the thermogenic functions
of brown adipocytes38–41.
3.2.1. Stimulation of glucose uptake by FGF21
In both 3T3-L1 adipocytes and human primary adipocytes,
FGF21 potently stimulates glucose uptake in an insulin-
independent manner5. Unlike insulin, FGF21 has no effectFigure 2 Pleiotropic metabolic actions of FGF21 in adipocytes.
FGF21 may act in an autocrine/paracrine manner to regulate
glucose uptake, lipid metabolism and PPARg activity in white
adipocytes, and increases the thermogenic activity of brown
adipocytes.on plasma membrane translocation of the glucose transporter
GLUT4, but induces the expression of GLUT1 through
transcriptional activation5. FGF21 stimulates p44/42 mito-
gen-activated protein kinase [or extracellular signal-regulated
kinases (ERK1/2)], which in turn phosphorylates and activates
the transcription factors serum response factor (SRF) and Ets-
like protein-1 (Elk-1) in 3T3-L1 adipocytes42 (Fig. 2). Acti-
vated SRF and Elk-1 act synergistically to transactivate the
GLUT1 gene by binding to the highly conserved serum
response element and E-26 motifs within the promoter region.
FGF21-induced phosphorylation of ERK1/2 and SRF/Elk1,
GLUT1 expression and glucose uptake are blunted in adipose
tissue of obese mice as compared to lean controls, suggesting
the existence of FGF21 resistance in obesity10,42. However,
whether or not FGF21-induced glucose uptake accounts for
its glucose-lowering effects remains to be determined.3.2.2. Regulation of lipolysis by FGF21
Conﬂicting data related to the roles of FGF21 on lipolysis has
been reported14,36,37. An early study in 3T3-L1 adipocytes
demonstrated that acute treatment of recombinant FGF21
increases lipolysis14. By contrast, another report found that
chronic treatment of 3T3-L1 adipocytes or human adipocytes
with either murine or human FGF21 for a period of 3 day has
no obvious effects on basal glycerol release, but leads to a
marked attenuation in noradrenaline- and forskolin-induced
lipolysis36. Likewise, a single injection of FGF21 acutely
reduces plasma free fatty acid (FFA) levels similar to its acute
effects on plasma glucose in db/db mice37. In vitro, FGF21 also
inhibits lipolysis in adipocytes during a short treatment and
decreases total lipase activity37.
The inhibitory effect of FGF21 on lipolysis is also con-
ﬁrmed by our recent study showing that FGF21 suppresses
GH-induced lipolysis through a negative feedback regulatory
loop33. In response to fasting/starvation, GH is released from
the pituitary gland to stimulate lipolysis in adipocytes for the
release of FFAs, which in turn induce hepatic FGF21
production via activation of PPARa. Elevated FGF21 in turn
acts as a negative feedback signal to terminate GH-induced
lipolysis in adipocytes. Such a feedback regulation not only
helps to maintain the balance of lipid distribution between
liver and adipose tissue, but also prevents lipotoxicity caused
by sustained elevation of FFAs. These ﬁndings also suggest
that the insulin-sensitizing effect of FGF21 may be attributed
to its ability in inhibiting the excessive elevation of circulating
FFA induced by the lipolytic hormones such as GH. The
suppressive effect of FGF21 on lipolysis during fasting is also
supported by a recent report in FGF21 KO mice11. However,
this study also suggests that FGF21 may play an opposite role
during the fed state.
In humans, the 24-h proﬁles of circulating FFAs closely
resemble those of FGF2143. There is a strong positive
association between the peak concentrations of circulating
FFAs and FGF21 during both the daytime and nighttime.
Noticeably, the peak time of circulating FFAs precedes that of
FGF21 by approximately 3–4 h, matching well with the
in vitro observation that incubation of human hepatocytes
with fatty acids for this period induces the production of
FGF2143. This study also support the existence of a feedback
regulation between FGF21 and FFAs may account for the
circadian rhythm of both factors in humans.
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Although the liver is the main contributor to circulate FGF21,
data from both animals and humans suggest that adipocytes
also express and secrete FGF21, which is under the control of
PPARg44,45. Notably, FGF21 expression in adipocytes is
increased in the fed state and is decreased in the fasting state,
a pattern opposite to that in hepatocytes46. Furthermore, this
study demonstrated the existence of a feed-forward loop
between FGF21 and PPARg in adipocytes, which may confer
the insulin-sensitizing actions of the anti-diabetic drugs thia-
zolidinediones (TZDs)46. FGF21 KO mice display defects in
PPARg signaling, including decreased body fat and reduced
expression of PPARg-dependent genes, and also resistant to
both the beneﬁcial insulin-sensitizing effects and the detri-
mental weight gain and edema side effects of the PPARg
agonist rosiglitazone. Such a change in FGF21 KO mice is
accompanied by a marked increase in the sumoylation of
PPARg, which blocks its transcriptional activity and possibly
by promoting corepressor recruitment. This unexpected ﬁnd-
ing suggests that FGF21 has two separate physiological
functions: as an endocrine factor secreted by the liver to
coordinate the adaptive response to fasting/starvation, and as
an autocinre factor induced in WAT during the fed state to
regulate adipocyte function.
3.2.4. FGF21 and thermogenesis in brown adipocytes
Brown adipose tissue (BAT) is the main site of nonshivering
thermogenesis in rodents and human neonates, and functional
BAT may also exist in human adults47,48. A growing body of
evidence suggests FGF21 as an important thermogenic regulator
through its autocrine functions in brown adipocytes39,41. FGF21
expression in brown adipocytes of mice is relatively high
compared to white adipocytes, and is strongly induced by either
cold challenge or b-adrenergic agonists through induction of
cAMP and p38 MAP kinase39,41. Notably, cold challenge
increases circulating FGF21 without affecting hepatic FGF21
expression, suggesting that BAT becomes the major source of
circulating FGF21 under this circumstance. Injection of FGF21
into neonatal mice increases body temperature, enhances the
expression of genes involved in thermogenesis and promotes
uncoupling respiration within BAT40. FGF21 is also implicated in
the conversion of white adipocytes into a ‘‘brown-like’’ state38.
FGF21 KO mice display an impaired ability to adapt to chronic
cold exposure, with diminished browning of WAT. This effect of
FGF21 may be attributed to its ability in enhancing PGC1a
expression in adipose tissue38. Indeed, FGF21 has been shown to
activate AMP-activated protein kinase and SirT1, thereby leading
to enhanced mitochondrial oxidation through activation of
PGC1a in adipocytes7.
In support of the role of FGF21 as a stimulator of
thermogenesis in BAT, transgenic expression or therapeutic
administration of FGF21 increases energy expenditure and
decreases body weight in mice8,14. However, FGF21 KO mice
exhibit a similar12 or even slightly decreased body weight and
fat mass as compared to wild-type controls46. The physiolo-
gical functions of FGF21 in BAT need further investigation.
3.3. Central FGF21 actions
The brain plays a central role in controlling body fat content
and glucose and lipid homeostasis49. FGF21 can cross blood–brain barrier and enter the brain in a non-saturable manner50,
and has been proposed as a missing link between the brain and
the peripheral metabolic tissues51. Chronic intracerebroven-
tricular infusion of recombinant FGF21 into the lateral
cerebral ventricle increases food intake, energy expenditure,
and hepatic insulin sensitivity in male obese rats52, suggesting
that the metabolic effects of FGF21 are mediated in part
through its central actions. FGF21 has also been proposed as
a possible signal peptide to convey the information of PPARa
activation from the liver to brain to induce ‘‘torpor’’, a state of
decreased physiological activity in animals characterized by a
reduced body temperature and metabolic rate as an adaptive
response to conserve energy53. Administration of the PPARa
agonist bezaﬁbrate induces a time-dependent torpor-like
phenomenon and concurrently increases hepatic FGF21 pro-
duction in mice53,54. Interestingly, both transgenic expression
and therapeutic administration of FGF21 stimulate torpor in
mice14. Likewise, intracerebroventricular injection of neuro-
peptide Y (NPY) also reliably induces torpor-like hypother-
mia that resembles natural torpor in hamsters55. Since the
PPARa agonist bezaﬁbrate also stimulate NPY production, it
has been suggested that PPARa controls torpor and circadian
clock through the FGF21-NPY axis53. However, there is
currently no evidence demonstrating that FGF21 acts as an
upstream regulator of NPY.3.4. The pancreatic actions of FGF21
Several independent studies on different animal models have
consistently demonstrated the protective effects of FGF21
against various pancreatic injury as well as b-cell dysfunc-
tion56,57. FGF21 KO mice are more susceptible to cerulein-
induced pancreatitis (CIP), whereas FGF21 transgenic mice
are resistant to develop this acute pancreatic damage56. The
protection of FGF21 against CIP is possibly attributed to its
ability in activation of ERK1/2 in pancreatic stellate cells.
FGF21 expression can be detected in human, rat and mouse
pancreatic islets as well as in rat primary b-cells and INS-1E
cells57. Short-term administration of FGF21 lowers plasma
insulin concentrations in both healthy and db/db mice,
whereas long-term treatment with FGF21 increases both the
number of islets and the amount of insulin per islet in db/db
mice. However, FGF21 did not affect islet cell proliferation.
Treatment of rat islets or INS-1E cells causes a partial
protection against glucotoxicity- and cytokine-induced apop-
tosis, possibly by activation of both ERK1/2 and Akt signal-
ing pathways57. In addition, FGF21 suppresses glucagon
secretion from isolated rat islets and reduces plasma glucagon
concentrations in mice5. FGF21 also enhances islet engraft-
ment in mouse synergetic islet transplantation model58.
Transplantation of islets pre-treated with FGF21 for three
days into streptozocin-induced diabetic mice restores normo-
glycemia by suppressing islet graft loss.
In humans, plasma levels of FGF21 are elevated in patients
with type 2 diabetes, but are decreased in patients with type 1
diabetes and latent autoimmune diabetes59. Furthermore,
plasma FGF21 levels correlate inversely with titers of auto-
immune antibodies against glutamic acid decarboxylase and
insulinoma-associated protein 2, but positively with C-peptide,
suggesting that FGF21 is functionally related to insulin
secretion in man. Nevertheless, there is currently no direct
Metabolic actions of FGF21 355evidence supporting FGF21 as a physiological regulator of
FGF21 secretion. Further studies on the impact of FGF21
deﬁciency on b size and number as well as insulin secretion
proﬁles in a type-1 or type-2 diabetic model should help clarify
the physiological roles of FGF21 in islet biology.4. FGF21 signaling and FGF21 resistance
Due to a lack of the heparin-binding property, FGF21 itself is
not sufﬁcient to bind the classical FGFRs, but requires the
recruitment of the single-pass transmembrane protein bKlotho
as a co-receptor42,60–62, through its direction with the carboxyl
terminus of FGF2163. Several in vitro studies demonstrated the
essential role of bKlotho in conferring FGF21-induced
ERK1/2 activation and glucose uptake in adipocytes42,60–62.
Unlike the ubiquitous expression pattern of FGFRs, bKlotho
expression is restricted to a number of tissues (adipose tissue,
liver, brain and pancreas)64, which may explain the tissue
selectivity of the FGF21 targets. However, another study on
bKlotho KO mice demonstrated that bKlotho is not essential
for FGF21 signaling in adipose tissue in vivo, suggesting the
existence of bKlotho-independent signaling pathways with the
involvement of unknown co-factors65. However, as neither the
pharmacological effects nor the physiological activities of
FGF21 has been evaluated systematically in bKlotho KO
mice, the role of bKlotho in FGF21 signaling needs further
clariﬁcation in the future.
Among the multiple isoforms of FGF receptors, FGFR1
has been suggested as the main form for FGF21 actions64.
Notably, FGF21 resistance, a phenomenon reminiscence of
insulin resistance, has been observed in obese mice10. Adipose
tissue isolated from dietary obese mice exhibits impaired
responsiveness to FGF21 on activation of ERK1/2, induction
of GLUT1 expression and stimulation of glucose uptake42,
and such an impairment is associated with decreased expres-
sion of FGFR1c and bKlotho66.
In humans, plasma levels of FGF21 are signiﬁcantly
elevated in obese subjects44 and patients with a cluster of
obesity-related disorders, including nonalcoholic fatty liver
disease27,67,68, type 2 diabetes69, chronic kidney disease70 and
coronary heart disease71. It is currently unclear whether the
elevated plasma FGF21 under these pathological conditions is
due to FGF21 resistance or a compensatory response. It is
also possible that the physiological functions of FGF21 in
humans are different from rodents.5. Concluding remark and future prospective
Since the ﬁrst demonstration that FGF21 acts as a potent
metabolic regulator to decrease hyperglycemia5, it has
attracted great interest due to its multiple beneﬁts on obe-
sity-related medical complications. Furthermore, it serves as
the downstream target of both PPARa and PPARg agonists,
which have been widely used for treatment of hyperlipidemia
and insulin resistance. Therefore, FGF21 alone may be
sufﬁcient to confer the therapeutic beneﬁts of PPARa and
PPARg dual agonists to improve glucose and lipid metabolism
in both liver and adipose tissue. However, the therapeutic
application of FGF21 is limited by its short circulating half-
life72, and difﬁculties in producing highly active recombinantFGF21 in large quantities for long-term treatment. In this
connection, recombinant human FGF21 with polyethylene
glycol (PEGylation) have been shown to be more stable and
potent in reducing blood glucose and triglyceride levels in the
type 2 diabetic animals73,74. It is also of importance to note
that chronic treatment of FGF21 may also cause severe side
effects such as skeletal fragility75, which may represent another
challenge for therapeutic application of FGF21. Furthermore,
in light of the elevated plasma levels of FGF21 in patients with
obesity-related cardio-metabolic disorders, whether or not
therapeutic intervention with FGF21 is effective in these
patients remains questionable at this stage.
From a physiological perspective, FGF21 represents a key
missing link in fasting biology that mediates the cross-talk
between multiple metabolic organs, and therefore provides
unique insights in understanding the adaptive responses to
fasting/starvation. There appears to be a dichotomy between
the physiological effects of endogenous FGF21 and pharma-
cological actions of recombinant FGF21. Our understanding
on the molecular pathways underlying the metabolic actions
of FGF21 is still in its infancy. Further studies on this aspect
may help to develop therapeutic agents for treatment and
prevention of obesity-related medical complications through
selective activation of FGF21 signaling pathways in its major
targets.
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